Piper Sandler analysts said in a note that Hims should be fine "for the time being." They noted, however, that the FDA's move does signal that it's "not giving much leeway for the compounders."
Motivated by these previous reports and the simplicity of the HIP approach, we evaluated the HIP of GSH-AuNCs with DDA (we avoided the use of quaternary ammonium phase transfer agents due to their toxicity)
However, downstream effects such as body composition changes, improved sleep quality, or visceral fat reduction typically require consistent administration over several weeks to months of research
Per kg dosage in mice does not scale to humans
Please note that compounded medications are not reviewed by the FDA for safety, quality, or efficacy
All three are by the same author